Short Interest in Bioxytran, Inc. (OTCMKTS:BIXT) Increases By 2,418.3%

Bioxytran, Inc. (OTCMKTS:BIXT) saw a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 10,300 shares, an increase of 2,418.3% from the February 12th total of 409 shares. Based on an average trading volume of 481,876 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s stock are sold short. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 481,876 shares, the short-interest ratio is currently 0.0 days.

Bioxytran Trading Down 8.1%

BIXT traded down $0.00 during midday trading on Tuesday, reaching $0.04. The company’s stock had a trading volume of 145,431 shares, compared to its average volume of 219,554. Bioxytran has a 1 year low of $0.03 and a 1 year high of $0.23. The stock’s 50-day moving average is $0.05 and its 200-day moving average is $0.07. The firm has a market capitalization of $4.75 million, a price-to-earnings ratio of -1.40 and a beta of 2.14.

Bioxytran Company Profile

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.